ABEC Launches ATB™-2100 Platform to Transform Advanced Therapy Manufacturing

BETHLEHEM, Pa., Nov. 5, 2026 /PRNewswire/ -- ABEC, a global leader in engineered solutions and services for biopharmaceutical manufacturing, today announced the commercial launch of the ATB™-2100 Advanced Therapy Bioreactor, a breakthrough single-use cell expansion technology designed to address the cell and gene therapy industry's growing need for scalable, reproducible, and automated manufacturing.

The ATB™-2100 represents a new approach to advanced therapy processing, combining unprecedented process control and scalability in a fully-closed and automated platform that supports cell expansion from preclinical development through commercial manufacturing. Designed for the most difficult cell and gene therapy applications, the platform has successfully demonstrated the expansion of T-cells, induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and other emerging modalities.

At the core of the ATB™-2100 is ABEC's proprietary network of hollow-fiber perfusion membranes, which continuously deliver nutrients and gases throughout the culture environment while removing metabolic waste. The system emulates the human circulatory system with a diffusion-based, low-shear environment that is ideal for cell growth. Exceptionally high cell densities and viabilities are achieved because cells are not exposed to the stresses commonly associated with other platforms.

Unlike other cell expansion technologies that require process redevelopment during scale-up, the ATB™ platform maintains a consistent membrane surface-area-to-volume ratio across bioreactor volumes from 200mL to 10L, enabling direct translation of process conditions from early-stage development through commercial production. This unique scalability significantly reduces development timelines, minimizes risk during technology transfer, and reduces time to market.

"Cell and gene therapies continue to face significant development and manufacturing challenges that limit scalability, increase costs, and slow commercialization," said Scott Pickering, Chief Executive Officer of ABEC. "The ATB™-2100 overcomes these barriers and represents another industry-changing advancement pioneered by ABEC."

For more information about the ATB™-2100 Advanced Therapy Bioreactor Platform, visit www.abec.com or contact info@abec.com.

About ABEC

ABEC is a leading global provider of engineered solutions and services for biopharmaceutical manufacturing. With more than 50 years of innovation, ABEC combines bioprocess equipment expertise, engineering, manufacturing, automation, and services to support the development and commercialization of life-changing therapies. From R&D through commercial implementation and lifecycle support, ABEC delivers innovative solutions that enhance productivity, accelerate time to market, and reduce overall cost to enable manufacturing success around the world.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

ABEC Launches ATB™-2100 Platform to Transform Advanced Therapy Manufacturing

WUHU, China, Nov. 5, 2026 /PRNewswire/ -- The 2026 JETOUR Global Technology Experience Day took place from October 20 to 23 under the theme "Future Travel Starts Now." Media, KOLs, and user representatives from around the world embarked on an immersive journey through Wuhu in Anhui Province, as well as Moganshan and Xiazhu Lake in Zhejiang Province. Spanning cities, mountains, and wetlands, the trip offered first-hand encounters with the technological achievements of JETOUR's "Travel+" philosophy and the travel lifestyle the brand champions.

Future Travel: Embedding Technology in Every Journey

The event put "travel" at its center, combining technological demonstrations, on-road driving, outdoor living, and ecological conservation to showcase JETOUR's vision of future travel. For JETOUR, technology shouldn't be confined to data or exhibition stands; it should be experienced and validated through real journeys.

Drawing on the Group's expertise in artificial intelligence, intelligent driving, smart cabins, and advanced chassis design, JETOUR turns cutting-edge technology into accessible experiences. The XWD Fully Automatic Intelligent AWD and GAIA All-Terrain Intelligent Architecture handle mountain terrain, water crossings, gravel roads, and steep slopes with confidence. Meanwhile, the C-DM hybrid system balances performance and energy efficiency for both city commuting and long-distance travel, complemented by intelligent driving assistance and efficient energy replenishment. A spacious, quiet, and versatile intelligent cabin makes every trip more enjoyable.

Bridging the World Through "Travel+"

Since its founding in 2018, JETOUR has remained committed to its "Travel+" strategy. The brand has entered over 100 countries and regions, with cumulative global sales surpassing 2.56 million units, and ranks No. 1 in SUV sales among Chinese brands in several overseas markets. This October, JETOUR invites global guests to witness how cutting-edge technology comes alive in real-world travel scenarios.

ABOUT JETOUR

Launched in 2018, JETOUR is committed to its "Travel+" strategy and has entered more than 100 countries and regions worldwide, with over 2,000 sales and after-sales service outlets and a global user base exceeding 50 million. Its portfolio includes the T-Series for the light off-road segment and the G-Series for the premium luxury off-road market.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Future Travel Starts Now: The 2026 JETOUR Global Technology Experience Day Was Held